CA3063622A1 - Anti-sirp.alpha. antibodies - Google Patents
Anti-sirp.alpha. antibodies Download PDFInfo
- Publication number
- CA3063622A1 CA3063622A1 CA3063622A CA3063622A CA3063622A1 CA 3063622 A1 CA3063622 A1 CA 3063622A1 CA 3063622 A CA3063622 A CA 3063622A CA 3063622 A CA3063622 A CA 3063622A CA 3063622 A1 CA3063622 A1 CA 3063622A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- cdr1
- cdr2
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171285 | 2017-05-16 | ||
| EP17171285.4 | 2017-05-16 | ||
| PCT/EP2018/062473 WO2018210793A2 (en) | 2017-05-16 | 2018-05-15 | ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3063622A1 true CA3063622A1 (en) | 2018-11-22 |
Family
ID=58714966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3063622A Pending CA3063622A1 (en) | 2017-05-16 | 2018-05-15 | Anti-sirp.alpha. antibodies |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11274159B2 (https=) |
| EP (2) | EP4400173A3 (https=) |
| JP (1) | JP7171617B2 (https=) |
| KR (1) | KR102714600B1 (https=) |
| CN (2) | CN118271443A (https=) |
| AR (1) | AR111630A1 (https=) |
| AU (1) | AU2018268304B2 (https=) |
| BR (1) | BR112019023754A2 (https=) |
| CA (1) | CA3063622A1 (https=) |
| CL (1) | CL2019003266A1 (https=) |
| DK (1) | DK3625259T3 (https=) |
| ES (1) | ES2981193T3 (https=) |
| FI (1) | FI3625259T3 (https=) |
| HR (1) | HRP20240924T1 (https=) |
| HU (1) | HUE067040T2 (https=) |
| LT (1) | LT3625259T (https=) |
| MX (1) | MX2019013749A (https=) |
| MY (1) | MY199247A (https=) |
| PL (1) | PL3625259T3 (https=) |
| PT (1) | PT3625259T (https=) |
| RU (1) | RU2771174C2 (https=) |
| TW (1) | TWI710574B (https=) |
| WO (2) | WO2018210793A2 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| KR102702926B1 (ko) * | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| BR112020026819A2 (pt) | 2018-06-29 | 2021-04-20 | Alector Llc | anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| JP7451520B2 (ja) * | 2018-11-15 | 2024-03-18 | ビョンディス・ビー．ブイ． | ヒト化抗ＳＩＲＰα抗体 |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20220119473A (ko) | 2019-12-24 | 2022-08-29 | 라노바 메디신즈 리미티드 컴파니 | 항-SIRPα 단클론성 항체 및 그것의 용도 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN115190886B (zh) * | 2020-02-20 | 2026-04-28 | 马斯特里赫特大学 | 循环bmp10（骨形态发生蛋白10）的检测方法 |
| JP2023525298A (ja) * | 2020-05-08 | 2023-06-15 | エレクトラ・セラピューティクス・インコーポレイテッド | Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用 |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
| JP7663265B2 (ja) * | 2020-11-30 | 2025-04-16 | クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド | 抗ＳＩＲＰα抗体またはその抗原結合断片および適用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| TW202317620A (zh) | 2021-06-04 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗ＳＩＲＰα抗體 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN116472351A (zh) * | 2021-08-17 | 2023-07-21 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| EP4396219A4 (en) * | 2021-09-03 | 2025-07-23 | Zymeworks Bc Inc | FC VARIANT WITH HIGH THERMAL STABILITY AND ATTENUATED EFFECTOR FUNCTION |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| US20240010701A1 (en) | 2022-06-01 | 2024-01-11 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118344476B (zh) * | 2024-05-16 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2001040307A1 (de) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| WO2013150043A1 (en) * | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| WO2013180200A1 (ja) * | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN106456749B (zh) * | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| CN114425077A (zh) * | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| WO2017068164A1 (en) * | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
-
2018
- 2018-05-15 CN CN202410367469.2A patent/CN118271443A/zh active Pending
- 2018-05-15 HR HRP20240924TT patent/HRP20240924T1/hr unknown
- 2018-05-15 KR KR1020197037055A patent/KR102714600B1/ko active Active
- 2018-05-15 MX MX2019013749A patent/MX2019013749A/es unknown
- 2018-05-15 TW TW107116450A patent/TWI710574B/zh active
- 2018-05-15 WO PCT/EP2018/062473 patent/WO2018210793A2/en not_active Ceased
- 2018-05-15 CA CA3063622A patent/CA3063622A1/en active Pending
- 2018-05-15 PL PL18729328.7T patent/PL3625259T3/pl unknown
- 2018-05-15 EP EP24169594.9A patent/EP4400173A3/en active Pending
- 2018-05-15 ES ES18729328T patent/ES2981193T3/es active Active
- 2018-05-15 PT PT187293287T patent/PT3625259T/pt unknown
- 2018-05-15 FI FIEP18729328.7T patent/FI3625259T3/fi active
- 2018-05-15 MY MYPI2019006658A patent/MY199247A/en unknown
- 2018-05-15 CN CN201880032714.7A patent/CN110799536B/zh active Active
- 2018-05-15 DK DK18729328.7T patent/DK3625259T3/da active
- 2018-05-15 HU HUE18729328A patent/HUE067040T2/hu unknown
- 2018-05-15 AU AU2018268304A patent/AU2018268304B2/en active Active
- 2018-05-15 JP JP2019563581A patent/JP7171617B2/ja active Active
- 2018-05-15 US US16/614,199 patent/US11274159B2/en active Active
- 2018-05-15 WO PCT/EP2018/062477 patent/WO2018210795A1/en not_active Ceased
- 2018-05-15 EP EP18729328.7A patent/EP3625259B1/en active Active
- 2018-05-15 BR BR112019023754A patent/BR112019023754A2/pt unknown
- 2018-05-15 RU RU2019141289A patent/RU2771174C2/ru active
- 2018-05-15 LT LTEPPCT/EP2018/062473T patent/LT3625259T/lt unknown
- 2018-05-16 AR ARP180101300A patent/AR111630A1/es not_active Application Discontinuation
-
2019
- 2019-11-14 CL CL2019003266A patent/CL2019003266A1/es unknown
-
2022
- 2022-02-02 US US17/591,231 patent/US11718681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3625259B1 (en) | Anti-sirpalpha antibodies | |
| JP7451520B2 (ja) | ヒト化抗ＳＩＲＰα抗体 | |
| CA3089768A1 (en) | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects | |
| TW202221029A (zh) | 抗cd93之構築體及其用途 | |
| TW202432594A (zh) | 抗ccr8抗體及其用途 | |
| US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| KR102955590B1 (ko) | 인간화 항-SIRPα 항체 | |
| RU2812199C2 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА | |
| US20250361320A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| WO2026096695A1 (en) | Anti-fucosyl-gm1 antibody drug conjugates | |
| KR20260044233A (ko) | 항-ceacam5 항체 약물 접합체 | |
| EA052794B1 (ru) | Новые антитела против fgfr2 | |
| TW202210515A (zh) | 抗ｃｄ３９之構築體及其用途 | |
| NZ787254A (en) | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240814 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250207 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250611 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250915 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |